Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

The role of topical timolol in wound healing and the treatment of vascular lesions: A narrative review.

Authors:
Azadeh Goodarzi Samaneh Mozafarpoor Milad Dodangeh Farnoosh Seirafianpour Mohamad Hasan Shahverdi

Dermatol Ther 2021 Mar 13;34(2):e14847. Epub 2021 Feb 13.

Department of Dermatology, Rasool Akram Medical Complex, Iran University of Medical Sciences (IUMS), Tehran, Iran.

Beta-2 adrenergic receptors are the only subgroup of beta-adrenergic receptors expressed in the membrane of large cells, including skin keratinocytes, fibroblasts, and melanocytes. Alterations in the function or concentration of β2 adrenoreceptors related to keratinocytes are associated with some skin conditions. Some findings suggest the role of β2 adrenoreceptors in maintaining the function and integrity of the epidermis. Beta-receptor antagonists can be systemically and topically effective in healing hemangioma, paronychia, vasculitis ulcer, tufted angioma, acute and chronic wounds. Most studies with a strong design on this subject deal with the systemic form, but recently, numerous case and group reports and smaller studies have focused on topical forms, especially topical timolol. The present comprehensive review study surveys the role of topical timolol in acute and chronic wound healing in the field of dermatology.

Download full-text PDF

 Source
http://dx.doi.org/10.1111/dth.14847DOI Listing
March 2021

Publication Analysis

Top Keywords

topical timolol
12
β2 adrenoreceptors
8
wound healing
8
role topical
8
acute chronic
8
systemic form
4
adrenoreceptors keratinocytes
4
focused topical
4
associated skin
4
studies focused
4
skin conditions
4
concentration β2
4
keratinocytes associated
4
healing hemangioma
4
topical forms
4
fibroblasts melanocytes
4
forms topical
4
melanocytes alterations
4
angioma acute
4
function concentration
4

Keyword Occurance

Similar Publications

Efficacy and Safety of Topical Timolol for the Treatment of Infantile Hemangioma in the Early Proliferative Stage: A Randomized Clinical Trial.

Authors:
Fania Z Muñoz-Garza Mónica Ríos Esther Roé-Crespo José Bernabeu-Wittel María Teresa Montserrat-García Luís Puig Ignasi Gich Eulalia Baselga

JAMA Dermatol 2021 Apr 7. Epub 2021 Apr 7.

Dermatology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Importance: Treatment of infantile hemangioma (IH) with topical timolol in the first 2 months of life (early proliferative phase) may prevent further growth and the need for treatment with oral propranolol. To our knowledge, no studies have determined whether beginning early treatment with timolol for IH is better than in other proliferative stages.

Objective: To evaluate the efficacy and safety of timolol maleate solution, 0. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Clinical Features, Prognostic Factors, and Treatment Interventions for Ulceration in Patients With Infantile Hemangioma.

Authors:
Esteban Fernández Faith Sonal Shah Patricia M Witman Katya Harfmann Flora Bradley Francine Blei Elena Pope Anwar Alsumait Deepti Gupta Isabela Covelli Jenna L Streicher Colleen Cotton Megha Tollefson Henry Nguyen Raegan Hunt Melissa Moore-Clingenpeel Ilona J Frieden

JAMA Dermatol 2021 Mar 31. Epub 2021 Mar 31.

Department of Dermatology, School of Medicine, University of California, San Francisco.

Importance: Ulceration is a common complication of infantile hemangioma (IH), which leads to substantial morbidity. Ulceration in IH has not been systematically studied since the advent of β-blocker therapy for IH.

Objectives: To examine treatment interventions used for ulceration in IH and identify clinical prognostic indicators of healing time. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Dry eye disease among Glaucoma patients on topical hypotensive medications, in a tertiary hospital, Ethiopia.

Authors:
Miraf Sahlu Abeba T Giorgis

BMC Ophthalmol 2021 Mar 30;21(1):155. Epub 2021 Mar 30.

Department of Ophthalmology, Menelik II Hospital, School of Medicine, College of Health Sciences, Addis Ababa University, P.O.Box 8079, Addis Ababa, Ethiopia.

Background: Dry eye disease is a multifactorial disease; causing various ocular symptoms with potential damage to the ocular surface. Applying hypotensive eye drops are presumed to initiate or exacerbate existing dry eye disease. The purpose of this study was to determine the frequency of signs and symptoms and severity of dry eye disease among glaucoma patients on topical hypotensive medications and controls. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Fractional erbium-doped yttrium aluminum garnet laser 2940 nm-assisted delivery of topical timolol solution for the treatment of histiocytoid hemangioma.

Authors:
Mohammed Albeshri Hadeel Alseleem Ahmed Alhumidi

JAAD Case Rep 2021 Mar 10;9:64-66. Epub 2021 Jan 10.

King Saud University, Riyadh, Saudi Arabia.

View Article and Full-Text PDF
March 2021
Similar Publications

[Type IV hypersensitivity to timolol].

Authors:
Silvio Espínola Dory Mora

Rev Alerg Mex 2020 Jul-Sep;67(3):293-296

Instituto de Prevision Social, Asunción, Paraguay.

Background: In recent years, there have been reports of contact dermatitis due to the beta-blockers that are used in the treatment of glaucoma, such as timolol, levubonolol, carteolol, or betaxolol.

Case Report: A 37-year-old male patient, who was diagnosed with bilateral primary open-angle glaucoma two years ago, was in therapy with dorzolamide and a topical β-adrenergic blocker (timolol) in drops twice a day. Months later, he reported conjunctival hyperemia, stinging, and inflammation of both eyelids, followed by erythematous dermatitis, which improved upon treatment discontinuation. Read More

View Article and Full-Text PDF
February 2021
Similar Publications